These findings emphasize the critical role of repeated, comprehensive genomic profiling in managing refractory ROS1-positive non-small cell lung cancer and establish cabozantinib as a viable therapeutic option in this specific resistance context. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.